Valeant on the Mend? H.C. Wainwright Remains on the Sidelines Until Pipeline Strength Proves Itself a Gains Maker

Valeant Pharmaceuticals (NYSE:VRX) is in the middle of making a comeback, as investors breathed a sigh of relief thanks to a largely successful third quarter print. However, H.C. Wainwright analyst Ram Selvaraju cannot help asking: is strength in Valeant’s Bausch + Lomb segment enough?

Story Continues